What caused PRFN.SW’s after-hours drop on 02 Jan 2026?

The after-hours decline to CHF0.0362 followed heavy trading: 2,937,350 shares versus average 859,130. The move reflects short-term selling and thin liquidity rather than a published earnings release; no earnings announcement is listed in the data feed.

What is Meyka AI’s view and grade for PRFN.SW?

Meyka AI rates PRFN.SW 67.07/100, Grade B with a HOLD suggestion. The grade factors in benchmark and sector comparisons, financial growth, key metrics and analyst consensus; it is informational and not investment advice.

What is the near-term price outlook for PRFN.SW?

Meyka AI's forecast model projects CHF0.065 over 12 months from CHF0.0362 today, implying 79.60% upside. Forecasts are model-based projections and not guarantees; liquidity and clinical catalysts remain key.

How risky is trading PRFN.SW right now?

High risk: the stock has limited market-cap data, low cash per share (CHF0.000736), negative operating cash flow per share (CHF-0.002131), and episodic volume spikes. Expect wide spreads and execution risk on the SIX.

CH Stocks

PRFN.SW down 8.12% to CHF0.0362 02 Jan 2026 after hours: high volume trade cue

ByHuzaifa Zahoor January 2, 2026January 2, 2026

PRFN.SW traded down 8.12% to CHF0.0362 in after-hours trading on 02 Jan 2026 on the SIX, driven by a surge to 2,937,350 shares, roughly 3.42 times average volume. PRFN.SW is the most active name in today’s microcap list, and the move highlights short-term seller pressure against thin liquidity. Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical firm based in Lausanne, shows low market capitalisation data and mixed classification in exchange records; we unpack the price action, ratios and a model forecast from our AI-powered market analysis platform.